Scott L. Tarriff

Biography

Mr. Tarriff brings more than 25 years of pharmaceutical experience to Synthetic Biologics. In January 2007, he formed Eagle Pharmaceuticals, Inc., a hospital specialty company focused on developing, distributing and in-licensing injectable IV products. Prior to forming Eagle, Mr. Tarriff served as President, Chief Executive Officer and Director of Par Pharmaceutical Companies, Inc. (NYSE: PRX). During his tenure at Par, he also served as the Executive Vice President of Business and as President and Chief Executive Officer of Par Pharmaceutical, Inc., the company's principal operating subsidiary. Mr. Tarriff joined Par following a 12-year career at Bristol-Meyers Squibb, where he held several positions of increased responsibility in both the brand and generic divisions. He also served as a Director of Clinical Data, Inc., a publicly-traded biopharmaceutical company which was acquired by Forest Laboratories, Inc. in 2011. Mr. Tarriff received an MBA from Rider College and an undergraduate degree from Pennsylvania State University.

Research Interest

biopharmaceutical , pharmaceutical analyst and managing investment Banking operation